APO-QUETIAPINE XR recall in Canada: May exceed acceptable intake limit
In plain language
This recall involves APO-QUETIAPINE XR tablets sold in Canada. It's being recalled because affected lots may exceed the acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP). Consult your healthcare provider before stopping use and follow the return steps in the official notice.
What to do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use or for any health concerns.
- Contact the recalling firm if you have questions.
- Report any health product related side effects to Health Canada.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
APO-QUETIAPINE XR 50mg
Lot: M2213002, M2213003, M2214445
APO-QUETIAPINE XR 200mg
Lot: M2214011, M2214015
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
- 2
Check the lot number
Lot numbers identify specific production batches.
Affected lots: M2213002, M2213003, M2214445, M2214011, M2214015
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
This recall involves APO-QUETIAPINE XR tablets sold in Canada. It's being recalled because affected lots may exceed the acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP). Consult your healthcare provider before stopping use and follow the return steps in the official notice.
What should consumers do?
Verify if your product is affected. Consult your healthcare provider prior to discontinuing use or for any health concerns. Contact the recalling firm if you have questions. Report any health product related side effects to Health Canada.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
A potential safety risk has been identified with this product. Stop using it immediately and follow the instructions in the official recall notice.
When was this product recalled?
This product was recalled on January 31, 2025.
Is the APO-QUETIAPINE XR brand affected by this recall?
Yes, APO-QUETIAPINE XR products are affected by this recall. This recall involves APO-QUETIAPINE XR tablets sold in Canada. It's being recalled because affected lots may exceed the acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP). Consult your healthcare provider before stopping use and follow the return steps in the official notice.